MC-Ala-Ala-Asn-PAB is a linker extracted from patent CN104147612A, page 14. MC-Ala-Ala-Asn-PAB can be used to synthesis the tumor microenvironment specific activated micromolecular targeted conjugate[1].
分子量
572.61
Formula
C27H36N6O8
CAS 号
1638970-44-1
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Chen L, et, al. Tumor microenvironment specific activated micromolecular targeted conjugate and application thereof. CN104147612A.
MC-Ala-Ala-Asn-PAB is a linker extracted from patent CN104147612A, page 14. MC-Ala-Ala-Asn-PAB can be used to synthesis the tumor microenvironment specific activated micromolecular targeted conjugate[1].
分子量
572.61
Formula
C27H36N6O8
CAS 号
1638970-44-1
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Chen L, et, al. Tumor microenvironment specific activated micromolecular targeted conjugate and application thereof. CN104147612A.
MC-Ala-Ala-Asn-PAB is a linker extracted from patent CN104147612A, page 14. MC-Ala-Ala-Asn-PAB can be used to synthesis the tumor microenvironment specific activated micromolecular targeted conjugate[1].
分子量
572.61
Formula
C27H36N6O8
CAS 号
1638970-44-1
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Chen L, et, al. Tumor microenvironment specific activated micromolecular targeted conjugate and application thereof. CN104147612A.
Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH Chemical Structure
CAS No. : 131287-39-3
规格
价格
是否有货
数量
25 mg
¥3000
In-stock
100 mg
¥9800
In-stock
200 mg
询价
500 mg
询价
* Please select Quantity before adding items.
Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH 相关产品
•相关化合物库:
Bioactive Compound Library Plus
Anti-Cancer Compound Library
生物活性
Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH (Fmoc-Asn(Ac3AcNH-beta-Glc)-OH) can be used in the synthesis of silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives. SiFA-octreotate analogues, as tumor imaging agents, are useful tool for the research of positron emission tomography (PET)[1].
分子量
683.66
Formula
C33H37N3O13
CAS 号
131287-39-3
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Wängler C, et al. One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET). Bioconjug Chem. 2010;21(12):2289-2296.
Z-Ala-Ala-Asn-AMC (Cbz-Ala-Ala-Asn-AMC) is the legumain substrate. Overexpressed legumain in 293 HEK-Leg cells potently cleaved CBZ-Ala-Ala-Asn-AMC[1].
体外研究 (In Vitro)
The first legumain fluorogenic substrate Cbz-Ala-Ala-Asn-AMC based on the P3-P2-P1 sequence Ala-Ala-Asn. The synthetic substrate Cbz-Ala-Ala-Asn-AMC is effectively cleaved by S. mansoni legumain and human legumain with Kms of 90 and 80 uM respectively[2][3].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量
565.57
Formula
C28H31N5O8
CAS 号
149697-16-5
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Stern L, Perry R, Ofek P, Many A, Shabat D, Satchi-Fainaro R. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug Chem. 2009;20(3):500-510.
[2]. James C. Powers, et al. Propenoyl hydrazides. US7482379B2.
[3]. Poreba M, et al. Counter Selection Substrate Library Strategy for Developing Specific Protease Substrates and Probes. Cell Chem Biol. 2016;23(8):1023-1035.
Gusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. Gusacitinib has anti-cancer activity in both solid and hematological tumor types[1].
IC50 & Target
IC50: 5-46 nM (SYK, JAK)[1].
体外研究 (In Vitro)
In mechanistic cell-based studies involving IgE and cytokine stimulations, Gusacitinib (ASN-002) strongly suppresses the SYK and JAK family kinase signaling pathways measured as pLAT and pSTAT levels, respectively. Gusacitinib (ASN-002) shows anti-proliferative activity in a broad panel of human cancer cell lines including DHL6, DHL4, OCI-LY10, H929, Pfeiffer, HT-1376, and Lovo, suggesting activity in both solid and hematological tumor types[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
In a multiple myeloma (H929) xenograft model, Gusacitinib (ASN-002) exhibits significant efficacy in inhibiting tumor growth (>95%). It also significantly delays the onset of hind limb paralysis in the human erythroleukemia (HEL) mouse model. Gusacitinib (ASN-002) has good oral bioavailability, metabolic stability, is not a Pgp substrate, and shows little to no inhibition of CYP450 isozymes. Gusacitinib (ASN-002) shows a favorable safety profile in rat and dog toxicology studies[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
分子量
460.53
Formula
C24H28N8O2
CAS 号
1425381-60-7
运输条件
Room temperature in continental US; may vary elsewhere.